SRT-2104
SRT-2104 is a drug candidate that is being developed by Sirtris Pharmaceuticals, a subsidiary of GlaxoSmithKline. It is a synthetic small molecule that is designed to activate the enzyme SIRT1, which is part of the sirtuin family of enzymes. SRT-2104 is being investigated for its potential to treat a variety of diseases, including type 2 diabetes, inflammation, and cancer.
Mechanism of Action[edit | edit source]
SRT-2104 is designed to activate SIRT1, an enzyme that is believed to play a key role in cellular health and longevity. SIRT1 is part of the sirtuin family of enzymes, which are involved in a variety of cellular processes, including DNA repair, cell survival, and metabolism. By activating SIRT1, SRT-2104 may help to promote cellular health and longevity, potentially offering benefits in the treatment of a variety of diseases.
Clinical Trials[edit | edit source]
SRT-2104 has been investigated in a number of clinical trials. These trials have explored the drug's potential in treating a variety of conditions, including type 2 diabetes, inflammation, and cancer. While the results of these trials have been promising, further research is needed to fully understand the drug's potential benefits and risks.
Potential Applications[edit | edit source]
The potential applications of SRT-2104 are broad, given the wide range of cellular processes that are influenced by SIRT1. The drug has been investigated for its potential to treat type 2 diabetes, a condition that is characterized by insulin resistance and high blood sugar levels. By promoting cellular health and metabolism, SRT-2104 may help to improve insulin sensitivity and lower blood sugar levels.
In addition, SRT-2104 has been studied for its potential to treat inflammation, a key factor in many diseases. By activating SIRT1, the drug may help to reduce inflammation and promote cellular health, potentially offering benefits in the treatment of diseases such as rheumatoid arthritis and inflammatory bowel disease.
Finally, SRT-2104 has been investigated for its potential to treat cancer. The drug may help to promote cellular health and longevity, potentially slowing the growth of cancer cells and improving patient outcomes.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
